Currently browsing: Inventions/Patents

Regulators Gone Wild

9/29/2016: Regulators gone wild.  I was with a famous orthopedic researcher today for lunch.  He is head of orthopedic research at two of America’s most prestigious universities.   Now listen to this.  He has a grant funded to study spinal cord injuries that will start soon, so there is no money available presently.  He wanted to study the rat’s spinal cord anatomy so that when the project starts, he will know exactly the approach and technique to this heretofore unexplored anatomy.   So he asked around the laboratory for any dead rats.  None were available.  So with his own money he purchased some rats and humanely euthanized them.  He then dissected the spine and spinal cord to see how best to perform their up coming research.   The regulators at his institution learned of this and called him in for an explanation.  He had violated the regulations by not registering his use of the rats, especially killing them.   He received a 6 week “sanction” and cessation from research activities as the punishment.   Rats are killed every day in every city in America.  It is legal.  Home Depot sells the poisons and traps.  People spend their own money to do this with no research in mind.  This is legal.  No reprisals and no regulators.    

US Patent Expanded by Further Claims Allowance

7/8/2016: I was granted additional claims on my previous patent: 8,263,069 Composition including anthocyanins and anthocyanidins for prevention and or treatment of articular cartilage associated conditions. September 11, 2012. The claims now include the direct intra articular injection of the phytochemical anthocyanin.  I now will submit an application for the phase I metabolite; protocatechuic acid for intra articular injection. The claims allowed were:  A method of inhibiting interleukin-1 (IL-1) induced glycosaminoglycoside (GAG) release in an arthritic joint of a subject, comprising administering into the arthritic joint of the subject, an intra-articular injection, a composition that is a solution consisting of an anthocyanin, glucose and a pharmaceutically acceptable carrier, wherein said glucose is a 5% solution, and wherein the anthocyanin is cyanidin-3-glucoside and said cyanidin-3-glucoside is administered at a dose of 0.002 mg to 100 mg per joint The method according to claim 1, wherein the composition increases gene expression of IGF-l in the arthritic joint. The method according to claim 1, wherein inhibiting interleukin-1 (IL-1) induced glycosaminoglycoside (GAG) release in the arthritic joint of a subject is associated with a chondroprotective effect in the joint of a subject. The method according to claim 1, wherein inhibiting interleukin-1 (IL-1) induced glycosaminoglycoside release in the arthritic joint of a subject is associated with a chondronutritive effect in the joint of a subject. The method of claim 1 wherein the joint is a synovial joint. A method for treating damaged cartilage in an arthritic joint in a subject, comprising the intra-articular injection of a composition consisting of an anthocyanin, glucose and a pharmaceutically acceptable carrier into the arthritic joint of a subject, wherein said glucose is a 5% solution, and wherein the anthocyanin is cyanidin-3-glucoside said cyanidin-3-glucoside is administered at a dose of 0.002 mg to 100 mg per joint The method according to claim 6, wherein the composition stimulates the production of insulin-like growth factor -1 (IGF-1) in the joint to regenerate the damaged cartilage. The method of claim 6 wherein the joint is a synovial joint.

Octarian Buddies Doing Business in D.C.

6/24/2016: Lanny with Jerry Gilbert, now octarians and buddies for almost 70 years are partnering in business venture today in Washington, D.C.  Making the rounds of Congressional staff, patent lawyers and wealth managment firms.  Gerald Gilbert is retired lawyer of Hogan and Lovells; still smart and energenic as ever to help Lanny find regulatory pathway for recently issued patents.

Another Patent Claim Granted

6/15/2016:  I learned today the my patent US 8,263,069 Composition including anthocyanins and anthocyanidins for prevention and or treatment of articular cartilage associated conditions. September 11, 2012 was granted expansion of the claims to include direct intra articular injection.  This took 4 years of legal argument to overcome the original objections. This paves the way for intra articular injection of arthritic joints to change the distructive chemistry and preserve and protect the present state of the cartilage.  To date there is not a sure way to restore articular cartilage, but working on it.

Patent Granted for Broad Spectrum Antibiotic

3/21/2016: I learned today that my US patent application for protocatechuic acid as a broad spectrum antibiotic and wound healing enhancer was granted.  This allows me to seek additional claims as well as advance other uses; i.e. sterilization of the skin prior to surgery to reduce this source of bacterial infection.  In addition, I will explore the sterilization of surgical implants at the time of surgery.

New Venture; DynaMotionMedical

3/20/16: I formed DynaMotionMedical to explore the use of nanotechnology to musculoskeletal diagnosis and measurement of post treatment outcomes. What I saw in golf with BlastMotion’s and Zepp’s use of this technology lead me to look into the applications for orthopedic conditions. With a unit comprised of miniature accelerometer, gyroscope and a magnetometer it is possible to see musculoskeletal movements not otherwise discerned by the human eye or video. For instance, motions that otherwise look normal will show interruption of acceleration, change in rotation and or x, y, z position in space. Pilot study proof of principle study shows this with tendon injury about the rotator cuff. Development is underway for diagnosing shoulder conditions as well as determining impending elbow ulnar collateral ligament tears. There is potential for a wearable device to prevent anterior cruciate ligament injury. Assessment of neck and back conditions that heretofore may be very puzzling should now be more exacting. Also interesting is the exposure with documentation of maligners. It will be possible to make a diagnosis based upon function, rather than static evidence like an x-ray and or MRI. The extent or magnitude of such conditions will be easily identified as well as the benefit of treatment. This technology will allow remote monitoring of patient’s progress by telemedicine for which there is a reimbursable billing code. A patent is pending.

Another Patent Granted; PTL

12/3/15: I was granted expanded patent claims on a previous patent of 2012; concerning the treatment of arthritic joints with certain phytochemicals; anthocyanins and anthocyanidins. 8,263,069 Composition including anthocyanins and anthocyanidins for prevention and or treatment of articular cartilage associated conditions. September 11, 2012. However the requests for a claim for direct intra articular injection was not granted. So after three years and lots of legal expense to contest their ruling we were granted the following claims which means I own the intellectual property for the intra articular injection of a specific and common anthocyanidin, cyanidin-3-glucoside to cause increased growth hormone IGF-1, inhibiting negative cytokine IL-1 which will induce the release of glycoaminoglycoside which in turn provides nutrition and protection to the articular cartilage of the arthritic synovial joint. Furthermore there is the potential to regenerate the damaged cartilage of an arthritic synovial joint. THE NEW CLAIMS 1. A method of inhibiting interleukin-1 (IL-1) induced glycosaminoglycoside (GAG) release in an arthritic joint of a subject, comprising administering into the arthritic joint of the subject an intra-articular injection of a composition consisting of an anthocyanin glucose and a pharmaceutically acceptable carrier, wherein said glucose is a 5% solution, and wherein the anthocyanin is cyanidin-3-glucoside and said cyanidin-3-glucoside is administered at a dose of 0.002 mg to 100 mg per joint or at a dose of 100 µM-200 µM. 2. The method according to claim 1, wherein the composition increases gene expression of IGF-l in the arthritic joint. 3. The method according to claim 1, wherein inhibiting interleukin-1 (IL-1) induced glycosaminoglycoside (GAG) release in the arthritic joint of a subject is associated with a chondroprotective effect in the joint of a subject. 4. The method according to claim 1, wherein inhibiting interleukin-1 (IL-1) induced glycosaminoglycoside release in the arthritic joint of a subject is associated with a chondronutritive effect in the joint of a subject. 5. A method for treating damaged cartilage, comprising the intra-articular injection of a composition consisting of an anthocyanin glucose and a pharmaceutically acceptable carrier into the arthritic joint of a subject, wherein said glucose is a 5% solution, and wherein the anthocyanin is cyanidin-3-glucoside said cyanidin-3-glucoside is administered at a dose of 0.002 mg to 100 mg per joint or at a dose of 100 µM-200 µM 6. The method according to claim 11, wherein the composition stimulates the production of insulin-like growth factor -1 (IGF-1) in the joint to regenerate the damaged cartilage. 7. A method of inhibiting interleukin-1 (IL-1) induced glycosaminoglycoside (GAG) release in the cartilage, comprising an intra-articular injection of a composition consisting of glucose, and a pharmaceutically acceptable carrier and a anthocyanin, wherein said anthocyanin is cyanidin-3-glucoside, and wherein said glucose is a 5% solution and wherein the cyanidin-3-glucoside is administered at a dose of 0.002 mg to 100 mg per joint or at a dose of 100 µM-200 µM.